Influenza Session

Emmanuel (Chip) Walter, MD, MPH
Chair, Influenza Work Group

Advisory Committee on Immunization Practices
October 25, 2018
Influenza Work Group

**ACIP Members**
- Emmanuel (Chip) Walter (Chair)
- Robert Atmar
- Hank Bernstein
- Peter Szilagyi

**Ex Officio Members**
- Sarah Browne (FDA)
- Cynthia Nolletti (FDA)
- Roshan Ramanathan (FDA)
- Chris Roberts (NIH)

**Consultants**
- Jeff Duchin
- Wendy Keitel
- Ruth Karron
- Jamie Loehr
- Ed Belongia

**Liaison Representatives**
- Kevin Ault (ACOG)
- Sarah Coles (AAFP)
- Sarah Despres (Consumer Representative)
- Buddy Creech (PIDS)
- Sandra Fryhofer (ACP; AMA)
- Ian Gemmill (NACI)
- Marie-Michèle Léger (AAPA)
- Susan Lett (CSTE)
- Flor Munoz (AAP)
- Kathy Neuzil (IDSA)
- William Schaffner (NFID)
- Rob Schechter (AIM)
- Ken Schmader (AGS)
- Patsy Stinchfield (NAPNAP)
- Rob Stirling (NACI)
- Tamara Sheffield (AHIP)
- Matthew Zahn (NACCHO)
Recap of Influenza Session, June 2018

- 2017-18 influenza vaccine effectiveness update
- 2017-18 influenza vaccine safety update
- Presentation of the SOMNIA study, a multinational study of narcolepsy following adjuvanted monovalent pandemic H1N1 influenza vaccines
- Presentation from Seqirus of results of a study of adjuvanted quadrivalent inactivated influenza vaccine in young children
- Summary of the 2018-19 recommendations
Workgroup Activities/Discussions Since February 2018

- Publication of the 2018-19 ACIP influenza vaccine statement
- Presentation of the PREVENT study of effectiveness of influenza vaccine in preventing hospitalization among pregnant women
- Presentation of study of Fluzone Quadrivalent (IIV4, Sanofi Pasteur) at a 0.5mL dose for children aged 6 through 35 months
Updated Labeling Information

- **Afluria** (IIV3, Seqirus) and **Afluria Quadrivalent** (IIV4, Seqirus):
  - Previously licensed for ages 5 years and older
  - In October 2018, age indication expanded to ages 6 months and older
  - Dose volume
    - Ages 6 through 35 months: 0.25 mL
    - Ages 36 months (3 years) and older: 0.5 mL

- Note: Five IIVs now licensed for 6 through 35 months*:
  - **Fluarix Quadrivalent** (IIV4, GSK) 0.5mL
  - **FluLaval Quadrivalent** (IIV4, GSK) 0.5 mL
  - **Fluzone Quadrivalent** (IIV4, Sanofi Pasteur) 0.25 mL
  - **Afluria** (IIV3, Seqirus) 0.25 mL
  - **Afluria Quadrivalent** (IIV4, Seqirus) 0.25 mL

*Dose for persons aged three and older is 0.5mL for all IIVs
Agenda Overview

- Influenza Vaccine Effectiveness in Preventing Influenza-Associated Hospitalizations during Pregnancy
  - Dr. Mark Thompson (CDC/NCIRD/Influenza Division)
- Fluzone Quadrivalent 0.5-mL dose for children aged 6 through 35 Months
  - Dr. Monica Mercer (Sanofi Pasteur)